NASDAQ:COLL
Collegium Pharmaceutical Stock News
$37.51
+0 (+0%)
At Close: May 03, 2024
Analysts Offer Insights on Healthcare Companies: Entasis Therapeutics Holdings (NASDAQ: ETTX) and Zynerba Pharmaceuticals (NASDAQ: ZYNE)
11:13am, Thursday, 12'th Mar 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Entasis Therapeutics Holdings (
ETTX
–
Research Report
) and Zynerba Pharmaceuticals (
ZYNE
–
Resea
Low Back Pain Clinical Trials Review: H1, 2020
12:33pm, Wednesday, 11'th Mar 2020
Dublin, March 11, 2020 -- The "Low Back Pain Clinical Trials Review: H1, 2020" report has been added to ResearchAndMarkets.com's offering. Low Back Pain.
Akebia Therapeutics (AKBA) Received its Third Buy in a Row
11:31am, Wednesday, 11'th Mar 2020
After Mizuho Securities and Piper Sandler gave Akebia Therapeutics (NASDAQ: AKBA) a Buy rating last month, the company received another Buy, this time
Akebia Therapeutics (AKBA) Received its Third Buy in a Row
11:31am, Wednesday, 11'th Mar 2020
After Mizuho Securities and Piper Sandler gave Akebia Therapeutics (NASDAQ:
AKBA
) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst
Ed Arce
maintained
Analysts Offer Insights on Healthcare Companies: InspireMD (NSPR) and Paratek Pharmaceuticals (PRTK)
11:31am, Wednesday, 11'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on InspireMD (NSPR) and Paratek Pharmaceuticals (PRTK) with
Analysts Offer Insights on Healthcare Companies: InspireMD (NYSE MKT: NSPR) and Paratek Pharmaceuticals (NASDAQ: PRTK)
11:31am, Wednesday, 11'th Mar 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on InspireMD (
NSPR
–
Research Report
) and Paratek Pharmaceuticals (
PRTK
–
Research Report
) with bu
KalVista Pharmaceuticals (KALV) Receives a Buy from Needham
08:12pm, Tuesday, 10'th Mar 2020
Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV) today and set a price target of $28.00. The company's shares
KalVista Pharmaceuticals (KALV) Receives a Buy from Needham
08:12pm, Tuesday, 10'th Mar 2020
Needham analyst
Serge Belanger
maintained a
Buy
rating on KalVista Pharmaceuticals (
KALV
–
Research Report
) today and set a price target of
$28.00
. The company’s shares closed last Monday at $1
Zynerba Pharmaceuticals (ZYNE) Received its Third Buy in a Row
05:41pm, Tuesday, 10'th Mar 2020
After H.C. Wainwright and Ladenburg Thalmann & Co. gave Zynerba Pharmaceuticals (NASDAQ: ZYNE) a Buy rating last month, the company received another
Zynerba Pharmaceuticals (ZYNE) Received its Third Buy in a Row
05:41pm, Tuesday, 10'th Mar 2020
After H.C. Wainwright and Ladenburg Thalmann & Co. gave Zynerba Pharmaceuticals (NASDAQ: ZYNE) a Buy rating last month, the company
COLL or NBIX: Which Is the Better Value Stock Right Now?
03:40pm, Tuesday, 10'th Mar 2020
COLL vs. NBIX: Which Stock Is the Better Value Option?
COLL or NBIX: Which Is the Better Value Stock Right Now?
03:40pm, Tuesday, 10'th Mar 2020
COLL vs. NBIX: Which Stock Is the Better Value Option?
Stocks Plunge Over 7% as Oil Concerns Join Coronavirus Fears
01:15pm, Tuesday, 10'th Mar 2020
Stocks Plunge Over 7% as Oil Concerns Join Coronavirus Fears
Why Collegium (COLL) Could Be an Impressive Growth Stock
12:42pm, Tuesday, 10'th Mar 2020
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Collegium (COLL).
Why Collegium (COLL) Could Be an Impressive Growth Stock
12:42pm, Tuesday, 10'th Mar 2020
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Collegium (COLL).
